A generic, twice-yearly injectable drug designed to prevent HIV transmission will be manufactured

Global Health Initiative Approves Lenacapavir Generic Version for 120 Countries

A generic, twice-yearly injectable drug designed to prevent HIV transmission will be manufactured and distributed at a cost of $40 per person annually across 120 low- and middle-income countries, following a provisional regulatory milestone announced in early November 2026.

Dr. Reddy’s Laboratories secured tentative approval from the United States Food and Drug Administration (FDA) for its generic version of lenacapavir. The pricing structure follows a landmark agreement established in September 2025 by Unitaid, the Wits Reproductive Health and HIV Institute (Wits RHI), the Clinton Health Access Initiative (CHAI), and Dr. Reddy’s Laboratories.

Originally developed by American pharmaceutical company Gilead Sciences, the medication obtained FDA approval in June 2025 after clinical trials demonstrated efficacy exceeding 99.9% in preventing HIV infections. The brand-name drug carries a commercial price tag of approximately $28,000 per year in the United States.

Pricing Comparison Between Original and Generic Formulations

| Formulation | Manufacturer | Annual Cost (US Markets / Target Regions) | Regulatory Status | Administration Schedule |
| :— | :— | :— | :— | :— |
| Lenacapavir (Original) | Gilead Sciences | ~$28,000 | FDA Approved (June 2025) | Bi-annual injection |
| Generic Lenacapavir | Dr. Reddy’s Laboratories | ~$40 | Tentative FDA Approval (November 2026) | Bi-annual injection |
| Standard Oral PrEP | Various | Varies (Comparable to $40 generic target) | Long-established availability | Daily pill |

The $40 annual price point for the generic formulation matches the cost of standard oral pre-exposure prophylaxis (PrEP) pills. Carmen Pérez-Casas, chief strategy officer for HIV and pandemic preparedness at Unitaid, noted that low- and middle-income populations historically waited a decade or longer for medical breakthroughs to cross international borders. With lenacapavir, that lag has narrowed to just over a year.

Implementation Timelines and Manufacturing Rollout Across Africa

Zambia is positioned among the first wave of recipients, with initial shipments of the generic treatment slated to arrive by late 2026. Broad deployment across all eligible countries will scale up through 2027.

Before the generic alternative entered the regulatory pipeline, more than 125,000 individuals across 10 African nations already accessed the original Gilead formulation through early-access programs, according to data from Unitaid.

While lenacapavir functions similarly to a vaccine in its mode of administration via biannual injections, health authorities emphasize that it does not train the immune system. Instead, it acts as a preventative option, removing the compliance hurdles associated with daily pill regimens that historically limited oral PrEP effectiveness.

Explain Why Generic Lenacapavir Remains Unavailable in the United States

How does lenacapavir work to prevent HIV?

Lenacapavir is used for pre-exposure prophylaxis (PrEP) against HIV. Administered twice a year by injection, it serves as a preventative option that does not work by training the immune system.

Why is the generic version not available in the United States?

The tentative approval granted by the US FDA allows manufacture and export to 120 designated developing nations under voluntary licensing agreements. Patent protections and exclusivity terms in the United States prevent the commercial sale of this generic formulation domestically.

Which companies hold licenses to produce generic lenacapavir?

Gilead Sciences issued voluntary licenses to six generic pharmaceutical manufacturers in late 2024. Among them, Dr. Reddy’s Laboratories is the first to achieve tentative FDA approval, while other entities such as Hetero are working to develop and provide the drug in the context of international efforts.